Prosecution Insights
Last updated: October 02, 2026

Examiner: NGUYEN, QUANG

Tech Center 1700 • Art Units: 1631 1633 1799

This examiner grants 38% of resolved cases

Analysis

Quang Nguyen is an examiner in Tech Center 1700 and Art Unit 1631. His record includes 749 resolved cases, which provides a basis for understanding his prosecution patterns. The allowance rate for these cases is 38.1%. This 38.1% rate indicates the frequency with which applications reach a grant under his review. Practitioners can use this figure to assess the challenging prosecution environment in Art Unit 1631.

The median days to allowance is 1480. This 1480-day figure represents the middle point of the timeline for applications that result in a patent grant. It serves as a practical benchmark for managing expectations regarding the duration of the examination process. The 1480-day median is a key metric for applicants to consider when planning their patent strategy and budgeting for prosecution costs in Tech Center 1700.

The data also shows an interview lift of 52.7%. This 52.7% lift represents the increase in the allowance rate associated with conducting an examiner interview. Practitioners should evaluate this 52.7% lift as a primary strategy for advancing prosecution. While the base allowance rate is 38.1%, the 52.7% lift suggests that direct communication is a highly effective tool for resolving outstanding issues and securing a grant. This lift provides a measurable basis for deciding whether to engage in an interview.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

38.0%
Allow Rate
-27.0% vs TC avg
813
Total Applications
+52.6%
Interview Lift
1482
Avg Prosecution Days
Based on 750 resolved cases, 2023–2026

Rejection Statute Breakdown

2.3%
§101 Eligibility
13.3%
§102 Novelty
38.7%
§103 Obviousness
31.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18314773 USE OF AAV-EXPRESSED M013 PROTEIN AS AN ANTI-INFLAMMATORY THERAPEUTIC Non-Final OA University of Florida Research Foundation, Incorporated
18191790 AAV-BASED GENE THERAPY FOR MULTIPLE SCLEROSIS Final Rejection University of Florida Research Foundation, Incorporated.
18558919 COMPOSITIONS AND METHODS RELATED TO THE TREATMENT OF OCULAR DISEASES IN EQUINES Final Rejection THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
18334530 METHODS AND COMPOSITIONS FOR CIRCULAR RNA MOLECULES Final Rejection The University of North Carolina at Chapel Hill
16761876 METHODS AND COMPOSITIONS FOR CIRCULAR RNA MOLECULES Non-Final OA The University of North Carolina at Chapel Hill
17999762 COMPOSITIONS AND METHODS FOR EPIGENOME EDITING Final Rejection The Regents of the University of California
17932026 METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE Final Rejection CureVac Manufacturing GmbH
15750745 METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE Final Rejection CureVac Manufacturing GmbH
16535042 INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF Non-Final OA Massachusetts Institute of Technology
17272194 GENE THERAPY FOR THE TREATMENT OF GALACTOSEMIA Final Rejection RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
18559667 PRODUCTION OF THERAPEUTIC MESENCHYMAL STEM CELL-DERIVED EXOSOMES Final Rejection BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17973773 VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST Final Rejection Novartis AG
18282139 TARGETED INSERTION VIA TRANSPOSITION Non-Final OA The Curators of the University of Missouri
17178972 GENERATING GABAergic NEURONS IN BRAINS Non-Final OA The Penn State Research Foundation
18517080 COMPOSITIONS AND METHODS OF TREATING USHER SYNDROME III Final Rejection CASE WESTERN RESERVE UNIVERSITY
18286847 HSV AMPLICON PACKAGING SYSTEM USING ENGINEERED CELLS Non-Final OA University of Pittsburgh - Of the Commonwealth System of Higher Education
18173485 METHODS FOR ENHANCING ANTI-TUMOR ACTIVITY OF EXHAUSTED T CELLS Final Rejection FRED HUTCHINSON CANCER CENTER
17260418 LIPID PARTICLE CONTAINING A-TYPE CpG OLIGODEOXYNUCLEOTIDE Non-Final OA TEIKYO UNIVERSITY
18563175 CRISPR-CAS3 SYSTEMS FOR TARGETED GENOME ENGINEERING Non-Final OA CORNELL UNIVERSITY
17773416 Recombinant CDKL5 Proteins, Gene Therapy and Production Methods Non-Final OA Amicus Therapeutics, Inc.
18156184 Oncolytic Vaccinia Virus Final Rejection Queen Mary University of London
18194383 GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT) Non-Final OA JunctuCell Biomed Manufacturing GmbH
16933773 NUCLEIC ACID PURIFICATION Final Rejection ZYMO RESEARCH CORPORATION

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month